ASC (PYCARD)

ASC (PYCARD)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">asc</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ASC</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>asc</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=ASC" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">358 edges</a></td>
</tr>
</table>

Overview

ASC (PYCARD)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">asc</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ASC</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>asc</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=ASC" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">358 edges</a></td>
</tr>
</table>

Overview

ASC (Apoptosis-associated Speck-like protein containing a CARD), also known as PYCARD (PYD and CARD domain containing), is a 195-amino acid adaptor protein that serves as a central node in innate immune signaling. Located on chromosome 16p11.2 (NCBI Gene ID: 29108, OMIM: 607315, UniProt: Q9Y258), ASC contains two protein-protein interaction domains: an N-terminal pyrin domain (PYD) and a C-terminal caspase recruitment domain (CARD). This bipartite architecture allows ASC to bridge pattern recognition receptors (PRRs) containing PYD domains with effector caspases containing CARD domains[@masumoto1999][@feng2005][@stutz2009].

ASC is best known as the adaptor protein required for the assembly and activation of the NLRP3 inflammasome, a multi-protein complex that activates caspase-1, leading to the maturation and release of pro-inflammatory cytokines IL-1β and IL-18, and the execution of pyroptotic cell death. Beyond inflammasome function, ASC also participates in NF-κB signaling, type I interferon induction, and can form caspase-1-independent inflammasomes. In the brain, ASC is expressed in microglia, astrocytes, and certain neurons, where it drives neuroinflammation and contributes to the pathogenesis of Alzheimer's disease, Parkinson's disease, ALS, and multiple sclerosis[@heneka2013][@walsh2014][@sarkar2020].

Gene and Protein Structure

Gene Architecture

The human ASC/PYCARD gene on chromosome 16p11.2:

• Single exon encoding the full-length 195-amino acid protein
• Compact gene structure consistent with its role as a signaling adaptor
• Promoter contains NF-κB and interferon-responsive elements
• Expression is induced by inflammatory stimuli including TNF-α, IFN-γ, and pathogen-associated molecular patterns (PAMPs)

Protein Architecture

ASC (UniProt: Q9Y258) is a 195-amino acid protein (approximately 22 kDa) composed of two death domain folds:

N-terminal Pyrin Domain (PYD) (residues 1-90):

• Six-helix bundle death domain fold
• Mediates homotypic interactions with PYD-containing proteins (e.g., NLRP3, AIM2)
• Critical for ASC filament formation through PYD-PYD interactions
• Responsible for the characteristic speck formation when ASC polymerizes

• Six-helix bundle death domain fold
• Mediates homotypic interactions with CARD-containing proteins (e.g., procaspase-1)
• Links inflammasome assembly to caspase activation
• Required for recruitment of procaspase-1 to the NLRP3 inflammasome complex

Post-translational Modifications

ASC undergoes regulatory modifications:

• Phosphorylation: TBK1 phosphorylates ASC at Ser194, enhancing its ability to form specks and amplifying innate immune responses[@hara2013]
• Ubiquitination: K63-linked ubiquitination of ASC regulates its stability and inflammasome activity
• SUMOylation: SUMO modification at specific lysine residues modulates ASC function

Inflammasome Assembly and Activation

The NLRP3 Inflammasome

ASC is the essential adaptor for the NLRP3 inflammasome, one of the most studied inflammasome complexes in neurodegeneration[@heneka2013][@lee2018]:

NLRP3 sensor: NLRP3 (NOD-like receptor family pyrin domain containing 3) is a cytoplasmic PRR that detects a wide range of danger signals including:

• Crystal aggregates (monosodium urate, silica, amyloid-β)
• Bacterial toxins (nigericin, gramicidin)
• ATP (P2X7 receptor activation)
• Mitochondrial dysfunction (mtDNA, ROS, cardiolipin)
• Lysosomal disruption (cathepsin release)
• Protein aggregates (alpha-synuclein, tau)

ASC recruitment: Activated NLRP3 undergoes nucleation and recruits ASC through PYD-PYD interactions. ASC filaments grow bidirectionally from the NLRP3 oligomer, forming a supramolecular assembly.

ASC Filament Formation

The structural basis of ASC inflammasome assembly involves cooperative polymerization[@lu2014]:

PYD filament formation:

• ASC PYD nucleates a helical filament through a mechanism resembling intermediate filament assembly
• Each ASC PYD engages four neighboring PYDs through 13 interaction interfaces
• Nucleation is the rate-limiting step; elongation is cooperative
• Filament formation creates a large scaffold for procaspase-1 recruitment

• After the PYD filament is established, the CARD domain forms a separate filament
• The CARD filament is typically shorter than the PYD filament
• Procaspase-1 is recruited through CARD-CARD interactions

Procaspase-1 Recruitment and Activation

Procaspase-1 recruitment: Multiple procaspase-1 molecules (typically 8-10) are recruited to the CARD filament through CARD-CARD interactions.

Proximity-induced autoactivation: Procaspase-1 molecules in the filament are brought into proximity sufficient for trans-processing. Each molecule cleaves its neighbor at the inter-domain linker (p20/p10 junction), generating the active heterodimer (p20/p10). Two heterodimers assemble into the active caspase-1 tetramer[@boucher2018].

Substrate cleavage: Active caspase-1 cleaves:

• Pro-IL-1β → mature IL-1β (active cytokine, released extracellularly)
• Pro-IL-18 → mature IL-18 (active cytokine, released extracellularly)
• Gasdermin D (GSDMD) → GSDMD-N (pore-forming fragment that executes pyroptosis)[@shi2016]
• Pro-caspase-7 → caspase-7 (amplifies cell death)
• HMGB1 → released as a damage-associated molecular pattern

Other Inflammasomes Using ASC

ASC serves as an adaptor for multiple inflammasome complexes:

NLRP1 inflammasome: In humans, NLRP1 assembles with ASC to activate caspase-1 in response to anthrax lethal toxin and certain viral infections.

NLRC4 inflammasome: NLRC4 (Ipaf) can recruit ASC to amplify caspase-1 activation, particularly in response to bacterial flagellin and type III secretion system components.

AIM2 inflammasome: AIM2 detects cytosolic double-stranded DNA and recruits ASC through PYD interactions. The AIM2-ASC inflammasome activates caspase-1 in response to viral and bacterial DNA.

Pyrin inflammasome: The pyrin domain-containing protein MEFV (pyrin) forms an ASC-dependent inflammasome activated by RhoA GTPase modification.

ASC Speck and Intercellular Propagation

ASC Speck Structure and Release

The ASC speck is a single macrostructure per cell that forms upon inflammasome activation[@barb2015][@hara2018]:

Structure: The ASC speck is approximately 1-3 μm in diameter, visible by light microscopy as a single perinuclear dot. Electron microscopy reveals a dense fibrillar structure composed of ASC PYD filaments.

Release: ASC specks are released from pyroptotic cells into the extracellular space. The speck maintains its intact structure and inflammatory activity after release.

Stability: Released ASC specks are remarkably stable and can persist in the extracellular environment for extended periods.

ASC Specks as Propagation Seeds

Extracellular ASC specks function as potent inflammatory triggers and propagation seeds[@walsh2014][@durairaj2018][@volchuk2020]:

Inflammasome activation in recipient cells: ASC specks are taken up by neighboring cells through phagocytosis. Once inside, the speck nucleates new ASC filament formation, directly activating the NLRP3 inflammasome without requiring a new priming signal. This represents a form of "inflammatory contagion."

Alpha-synuclein propagation: In Parkinson's disease, extracellular ASC specks can induce additional ASC speck formation in recipient cells while simultaneously promoting alpha-synuclein aggregation. ASC specks physically co-aggregate with alpha-synuclein, and the NLRP3 inflammasome activation enhances alpha-synuclein pathology propagation[@venkatachalam2016].

Tau pathology propagation: In Alzheimer's disease, ASC specks released from microglia can propagate NLRP3 inflammasome activation to other cells. The released specks also enhance tau pathology spread through mechanisms involving ASC-dependent signaling cascades[@volchuk2020].

Intercellular communication: ASC specks broadcast a "danger signal" to the local environment, amplifying inflammation beyond the initially activated cell.

Systemic Inflammation

ASC speck release contributes to systemic inflammation:

• Circulating ASC specks have been detected in animal models and human inflammatory conditions
• ASC specks can activate endothelial cells, promoting leukocyte recruitment
• Systemic ASC may contribute to the chronic inflammation observed in neurodegenerative diseases

Role in Alzheimer's Disease

NLRP3/ASC Inflammasome in AD

The NLRP3/ASC inflammasome is activated in Alzheimer's disease and contributes to pathology progression[@heneka2013][@sarkar2020][@liu2019]:

Microglial activation: Aβ plaques activate the NLRP3 inflammasome in microglia through multiple mechanisms:

• Aβ crystals directly activate NLRP3
• Aβ-induced lysosomal damage releases cathepsins that activate NLRP3
• Aβ-triggered mitochondrial dysfunction generates ROS that activate NLRP3
• P2X7 receptor activation by extracellular ATP (released from dying neurons) synergizes with Aβ

IL-1β in AD pathogenesis: IL-1β produced by the inflammasome promotes:

• Chronic neuroinflammation that sustains microglial activation
• Impaired amyloid clearance (IL-1β inhibits Aβ phagocytosis)
• Enhanced tau phosphorylation through IL-1R1 signaling
• Synaptic dysfunction and memory impairment

Interaction with Tau Pathology

The NLRP3/ASC inflammasome and tau pathology form a vicious cycle[@sarkar2020][@volchuk2020]:

IL-1β promotes tau phosphorylation: IL-1β activates several kinases (GSK-3β, CDK5, p38 MAPK) that phosphorylate tau at AD-relevant epitopes.

Tau drives inflammasome activation: Hyperphosphorylated tau oligomers activate the NLRP3 inflammasome in microglia, creating a positive feedback loop.

ASC specks enhance tau propagation: Extracellular ASC specks promote the cell-to-cell spread of tau pathology. Tau fibrils co-localize with ASC specks in AD brain tissue.

Therapeutic targeting: MCC950, a potent NLRP3 inhibitor, reduces both amyloid pathology and tau pathology in AD mouse models, demonstrating the therapeutic potential of targeting the ASC-dependent inflammasome[@lee2018].

Therapeutic Implications

NLRP3 inhibitors: MCC950, as well as other NLRP3 inhibitors (dapansutrile, OLT1177), reduce AD pathology and cognitive deficits in preclinical models by blocking ASC-dependent inflammasome assembly.

IL-1β blockade: IL-1 receptor antagonists (anakinra, canakinumab) are being investigated for AD. Canakinumab (anti-IL-1β antibody) showed mixed results in clinical trials.

ASC knockout: ASC deficiency protects against amyloid pathology, tau pathology, and cognitive deficits in mouse models, validating ASC as a therapeutic target.

Role in Parkinson's Disease

NLRP3/ASC in PD Pathogenesis

The NLRP3/ASC inflammasome is activated in the substantia nigra and striatum in PD models and patients[@walsh2014][@venkatachalam2016]:

Alpha-synuclein aggregation: Misfolded alpha-synuclein activates the NLRP3 inflammasome in microglia through:

• Direct interaction with the NLRP3 protein
• Lysosomal rupture and cathepsin release
• Mitochondrial dysfunction triggered by alpha-synuclein oligomers

Dopaminergic neuron vulnerability: ASC inflammasome activation in the substantia nigra contributes to dopaminergic neuron loss through:

• IL-1β-mediated toxicity to dopaminergic neurons
• Pyroptotic death of microglia and astrocytes
• Propagation of inflammation through ASC speck release

Evidence from Models and Patients

Animal models:

• MPTP and 6-OHDA models show NLRP3 inflammasome activation in the SNpc
• Alpha-synuclein transgenic mice show ASC speck formation in microglia
• ASC knockout or NLRP3 knockout protects dopaminergic neurons

• Increased NLRP3, ASC, and caspase-1 in SNpc and striatum of PD patients
• ASC specks detectable in the CSF of PD patients
• Correlation between inflammasome markers and disease severity

Therapeutic Targeting

NLRP3 inhibitors: MCC950 and other inhibitors protect dopaminergic neurons in PD models. ISP (insulin signal potentiator) also reduces NLRP3 activation.

ASC-targeting approaches: Strategies to block ASC speck formation or release are being developed.

Anti-inflammatory approaches: Broad anti-inflammatory strategies (minocycline, NSAIDs) show variable efficacy in PD models and clinical trials.

Role in ALS and MS

Amyotrophic Lateral Sclerosis

In ALS, the NLRP3/ASC inflammasome contributes to motor neuron death and glial activation[@walsh2014]:

Motor neuron vulnerability: Motor neurons express NLRP3 and ASC, making them capable of forming inflammasomes in response to protein aggregates (SOD1, TDP-43, FUS).

Glial activation: Activated microglia and astrocytes in ALS release IL-1β and ASC specks, amplifying inflammation in the spinal cord.

TDP-43 pathology: TDP-43 aggregates activate the NLRP3 inflammasome, connecting proteinopathy with neuroinflammation.

Therapeutic: NLRP3 inhibitors extend survival in SOD1 mouse models.

Multiple Sclerosis

In MS and its animal model EAE:

Myelin antigen presentation: The NLRP3 inflammasome is activated in microglia and macrophages responding to myelin debris.

Th1/Th17 polarization: IL-1β from inflammasome activation promotes Th1 and Th17 cell differentiation and migration to the CNS.

Blood-brain barrier disruption: Inflammasome activation in endothelial cells contributes to BBB breakdown.

Therapeutic: NLRP3 inhibitors reduce disease severity in EAE models.

ASC in NF-κB and Type I Interferon Signaling

NF-κB Activation

Beyond inflammasome function, ASC participates in NF-κB signaling[@xu2014]:

ASC as NF-κB activator: ASC itself can activate NF-κB through its PYD domain. Overexpression of ASC activates NF-κB, while ASC knockdown reduces NF-κB activation by certain stimuli.

Mechanism: ASC may serve as a platform for signaling molecules that activate the IKK complex. ASC associates with TRAF6 and other NF-κB pathway components.

Physiological relevance: ASC-dependent NF-κB activation contributes to the transcription of inflammatory genes including NLRP3, pro-IL-1β, and other cytokines.

Cross-talk with inflammasome: The NF-κB pathway provides the priming signal for NLRP3 upregulation, creating a feed-forward loop with the inflammasome.

Type I Interferon Induction

ASC contributes to type I interferon (IFN-α/β) responses to certain viral infections[@hara2013]:

TBK1 phosphorylation: ASC is phosphorylated at Ser194 by TBK1 (TANK-binding kinase 1), a kinase critical for IFN-β induction.

ASC-TBK1 complex: Upon viral infection, ASC forms a complex with TBK1 that enhances IRF3 activation and IFN-β production.

ASC in AIM2 inflammasome: The AIM2-ASC inflammasome can contribute to IFN-β induction in response to cytosolic DNA.

ASC-Dependent Pyroptosis

Gasdermin D Cleavage

ASC-driven caspase-1 activation leads to pyroptosis through gasdermin D (GSDMD) cleavage[@shi2016]:

GSDMD structure: GSDMD consists of an N-terminal pore-forming domain (GSDMD-N) and a C-terminal repressor domain (GSDMD-C). In the full-length protein, GSDMD-C autoinhibits GSDMD-N.

Caspase-1 cleavage: Active caspase-1 cleaves GSDMD at Asp276 (human), separating the N and C domains.

Pore formation: GSDMD-N translocates to the plasma membrane where it oligomerizes into pores (1-2 nm inner diameter). These pores:

• Release IL-1β and IL-18 (before cell lysis)
• Allow water influx, cell swelling, and osmotic lysis
• Represent the direct execution mechanism of pyroptotic cell death

Consequences of Pyroptotic Cell Death

Pro-inflammatory release: Pyroptotic cells release intracellular contents including:

• Mature IL-1β and IL-18 (highly pro-inflammatory)
• DAMPs (HMGB1, ATP, mitochondrial DNA, urate)
• ASC specks
• Other intracellular proteins

In the brain: Pyroptosis of microglia, astrocytes, and neurons contributes to the chronic neuroinflammation characteristic of neurodegenerative diseases.

Regulation of Pyroptosis

Autophagy: Autophagy degrades ASC specks and inflammasome components, limiting pyroptotic cell death.

Ubiquitination: K63-linked ubiquitination of ASC and NLRP3 targets them for autophagic degradation.

Anti-apoptotic proteins: Bcl-2 and related proteins can inhibit ASC-dependent signaling through unclear mechanisms.

Mermaid Diagram: ASC Inflammasome Assembly

Research Methods

Detection of ASC Activation

ASC speck immunostaining: Fluorescent labeling of ASC detects specks by microscopy. ASC speck-positive cells indicate inflammasome activation.

Caspase-1 activity: FLICA (fluorochrome-labeled inhibitors of caspases) reagents that covalently bind to active caspase-1.

IL-1β release: ELISA of cell culture supernatant or CSF.

ASC release: Western blot of extracellular fractions for ASC protein.

Live cell imaging: GFP-ASC allows real-time visualization of speck formation.

Mouse Models

ASC knockout mice: Asc^-/- mice are viable and show reduced inflammasome responses to NLRP3 activators.

ASC-GFP knock-in: GFP knocked into the Asc locus allows visualization of endogenous ASC speck formation.

Conditional ASC mice: Cell-type-specific ASC knockout (Cx3cr1-Cre for microglia, LysM-Cre for macrophages) enables dissection of ASC function in specific cell types.

In Vitro Models

Bone marrow-derived macrophages (BMDMs): Primary macrophages from mice for studying inflammasome activation.

Microglia cell lines: BV2, N9, and iPSC-derived microglia.

Neuron-microglia co-cultures: Studying cross-talk between neurons and microglia in neurodegeneration contexts.

Therapeutic Targeting

Small Molecule Inhibitors

MCC950: A potent and selective NLRP3 inhibitor that blocks ASC-dependent inflammasome assembly at the stage of NLRP3 oligomerization. MCC950 is neuroprotective in AD, PD, and ALS models.

Dapansutrile (OLT1177): An NLRP3 inhibitor in clinical trials for gout and inflammatory diseases. Being evaluated for neurodegenerative applications.

β-hydroxybutyrate: An endogenous ketone body that inhibits NLRP3 activation. Being investigated for its anti-inflammatory effects in neurodegeneration.

Biological Agents

Anakinra: IL-1 receptor antagonist (recombinant IL-1Ra). Being tested in AD clinical trials.

Canakinumab: Anti-IL-1β monoclonal antibody. Mixed results in AD trials.

Anti-ASC antibodies: Experimental antibodies targeting ASC to block speck formation and propagation.

Gene Therapy Approaches

ASC knockdown: siRNA or shRNA targeting ASC to reduce inflammasome activation.

Dominant-negative ASC: Expression of PYD-only or CARD-only constructs that act as dominant-negative inhibitors.

CRISPR/Cas9: Genome editing to knock out or inhibit ASC in relevant cell types.

Summary

ASC (PYCARD) is a central adaptor protein in innate immune signaling that serves as the essential bridge between pattern recognition receptors (particularly NLRP3) and effector caspases (particularly caspase-1). Through its dual PYD and CARD domains, ASC nucleates filament formation that culminates in the ASC speck, a hallmark of inflammasome activation. The ASC-dependent inflammasome drives the maturation and release of IL-1β and IL-18 and executes pyroptotic cell death through gasdermin D cleavage.

In neurodegenerative diseases, ASC plays critical roles: in Alzheimer's disease, ASC-mediated NLRP3 inflammasome activation contributes to amyloid pathology, tau phosphorylation, and cognitive decline; in Parkinson's disease, ASC specks propagate both neuroinflammation and alpha-synuclein aggregation; in ALS and MS, ASC-dependent inflammation drives motor neuron death and demyelination. ASC specks released from activated cells represent a unique mechanism of intercellular inflammatory propagation, making ASC an attractive therapeutic target for neurodegenerative disease modification.

See Also

• [NLRP3 Inflammasome Pathway](/mechanisms/nlrp3-inflammasome-pathway-neurodegeneration)
• [Pyroptosis](/mechanisms/pyroptosis)
• [Neuroinflammation](/mechanisms/neuroinflammation-pathways)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/als)
• [Multiple Sclerosis](/diseases/multiple-sclerosis)
• [Interleukin-1 Beta](/proteins/il-1beta)

External Links

• [NCBI Gene: PYCARD (ASC)](https://www.ncbi.nlm.nih.gov/gene/29108)
• [UniProt: Q9Y258](https://www.uniprot.org/uniprot/Q9Y258)
• [OMIM: 607315](https://www.omim.org/entry/607315)
• [Ensembl: ENSG00000103490](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000103490)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation](/hypothesis/h-fb56c8a0) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: SDC1
• [Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: LOX/LOXL1-4
• [Astroglial Gap Junction Coordination via Connexin-43 Phosphorylation Modulation](/hypothesis/h-3a901ec3) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: GJA1
• [Pericyte Contractility Reset via Selective PDGFR-β Agonism](/hypothesis/h-73e4340b) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: PDGFRB
• [Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modulation](/hypothesis/h-9eae33ba) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: KCNK2
• [Osmotic Gradient Restoration via Selective AQP1 Enhancement in Choroid Plexus](/hypothesis/h-0dea0ed5) — <span style="color:#ffd54f;font-weight:600">0.51</span> · Target: AQP1

Related Analyses:

• [Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving ASC (PYCARD) discovered through SciDEX knowledge graph analysis: